Former group director of clinical research Fred Eshelman, PharmD, rejoins Glaxo as VP-clinical operations. Eshelman left the company in 1984 to become director of clinical research at Boehringer Mannheim. In 1985, Eshelman started his own company Pharmaceutical Product Development in Wilmington, N.C.
You may also be interested in...
Trade group AdvaMed should be consulted on how to implement the Defense Production Act to boost testing and PPE production, CEO Scott Whitaker said in a letter to President Biden.
Following a successful offering by Prestige BioPharma in January, investors will keep their focus on another upcoming major listing by the SK Group's specialist vaccines arm SK Bioscience, which is likely to set the tone for the South Korean biopharma IPO market this year.
US FDA considering approach that is similar to, but more stringent than, influenza strain changes, CBER Director Marks says. Meanwhile, vaccine developers face challenge of when to change antigens to get the best results, NIH’s Graham notes. As FDA and sponsors gain more experience with tweaking the vaccines to account for new coronavirus variants and strains, the process may be expedited further.